Table 2.

Adverse events related to DN-101 reported in more than one patient

Adverse eventSeverity grade
Total (N = 38)Lowest dose at which event occurred (μg)
1234
Hyponatremia10 (26.3%)2 (5.6%)12 (31.6%)15
Hypoalbuminemia3 (7.9%)5 (13.2%)8 (21.1%)45
Hyperphosphatemia6 (15.8%)1 (2.6%)7 (18.4%)30
Hypercalcemia5 (13.2%)5 (13.2%)60
Proteinuria3 (7.9%)1 (2.6%)1 (2.6%)5 (13.2%)45
Creatinine clearance decreased3 (7.9%)1 (2.6%)4 (10.5%)60
Hypercalciuria*2 (5.3%)2 (5.3%)4 (10.5%)60
Hyperglycemia nitric oxide synthase2 (5.3%)2 (5.3%)4 (10.5%)30
Edema peripheral4 (10.5%)4 (10.5%)75
Fatigue3 (7.9%)3 (7.9%)45
Hypercholesterolemia2 (5.3%)1 (2.6%)3 (7.9%)135
Nausea3 (7.9%)3 (7.9%)15
Blood creatinine increased2 (5.3%)2 (5.3%)75
Diarrhea2 (5.3%)2 (5.3%)30
Dizziness2 (5.3%)2 (5.3%)135
Nasal congestion2 (5.3%)2 (5.3%)45
Thrombocytopenia2 (5.3%)2 (5.3%)60
  • * Graded by the investigator. No Common Toxicity Criteria grade available.